Navigation Links
Nektar Therapeutics Reports Third Quarter 2011 Financial Results

tive expense was $12.4 million in the third quarter of 2011 as compared to $10.2 million in the third quarter of 2010.  

Net loss for the third quarter ended September 30, 2011 was $24.1 million or $0.21 loss per share.

The company also announced upcoming presentations at medical meetings and scientific congresses scheduled for the fourth quarter of 2011:

Chemotherapy Foundation Symposium XXIX: Innovative Cancer Therapy for Tomorrow, New York, NY:

  • Session Title: "Evaluating Single-Agent NKTR-102 in Metastatic Breast Cancer"
  • Presenter: Edith Perez, MD
  • Session Type: Oral
  • Program Track: Breast Cancer
  • Date and Time: November 10, 2011, 1:25 PM Eastern Time

  • Neuroscience 2011: Society for Neuroscience Annual Meeting, Washington, DC:Preclinical data for NKTR-192, a new opioid drug candidate being developed to treat acute pain, will be presented.

  • Abstract Title: "Pharmacological characterization of an orally active opioid analgesic with rapid onset of activity and low abuse liability." Harrison, S., et al.  
  • Abstract/Poster Number: #178.10/NN20
  • Session Title/Track:  "Pharmacology Relevant to Pain, Addiction, and Development"
  • Date and Time: Nov 13, 2011, 8:00 AM - 12:00 PM Eastern Time

  • 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, San Francisco, CAPreclinical data for NKTR-102 in ovarian cancer will be presented.

  • Abstract Title: "Strong synergistic activity of NKTR-102 - pegylated liposomal doxorubicin (PLD) combination therapy in a nonclinical model of platinum-resistant A2780 human ovarian cancer." Hoch, et al.
  • Abstract/Poster Number: C209
  • Session Title/Track:  Topoisomerase Inhibitors
  • Date and Time: Nov 15, 2011, 12:30 PM - 2:30 PM Pacific Time

  • Conference Call to Discuss Third Quarter 2011 Financial

    SOURCE Nektar Therapeutics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
    2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
    3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
    4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
    5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
    6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
    7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
    8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
    9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
    10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
    11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
    Post Your Comments:
    (Date:9/16/2014)... , Sept. 16, 2014 Chindex International, Inc. ... announced that, at a special meeting of stockholders held ... agreement (the "Merger  Agreement") by and among the Company, ... Inc. ("Merger Sub"). Parent is an affiliate of TPG, ... Roberta Lipson , the CEO of the Company. ...
    (Date:9/16/2014)... , Sept. 16, 2014  This report analyzes the worldwide ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... and Rest of World. Annual estimates and forecasts are provided ... analysis is provided for these markets. Market data and analytics ...
    (Date:9/16/2014)... , Sept. 16, 2014 This report analyzes ... the following Product Segments: Devices, and Medication. The report provides ... , Japan , Europe ... , and Rest of World. Annual estimates and forecasts ... seven-year historic analysis is provided for these markets. Market data ...
    Breaking Medicine Technology:Chindex Stockholders Approve Merger 2Chindex Stockholders Approve Merger 3Global Digital Radiography Industry 2Global Digital Radiography Industry 3Global Digital Radiography Industry 4Global Digital Radiography Industry 5Global Digital Radiography Industry 6Global Digital Radiography Industry 7Global Digital Radiography Industry 8Global Digital Radiography Industry 9Global Digital Radiography Industry 10Global Digital Radiography Industry 11Global Digital Radiography Industry 12Global Digital Radiography Industry 13Global Digital Radiography Industry 14Global Digital Radiography Industry 15Global Digital Radiography Industry 16Global Digital Radiography Industry 17Global Digital Radiography Industry 18Global Digital Radiography Industry 19Global Digital Radiography Industry 20Global Digital Radiography Industry 21Global Digital Radiography Industry 22Global Foot Care Products Industry 2Global Foot Care Products Industry 3Global Foot Care Products Industry 4Global Foot Care Products Industry 5Global Foot Care Products Industry 6Global Foot Care Products Industry 7Global Foot Care Products Industry 8Global Foot Care Products Industry 9Global Foot Care Products Industry 10Global Foot Care Products Industry 11Global Foot Care Products Industry 12Global Foot Care Products Industry 13
    ... Switzerland, June 23 Debiopharm Group,(Debiopharm), a Swiss-based global ... of prescription drugs that target unmet medical,needs, announced that ... was launched in Germany in May 2009, by Dr ... on a preliminary basis in,Belgium. The effective commercial launch ...
    ... --Whole-Genome Searches Are Revealing Secrets of a Childhood Cancer-- , ... The Children,s Hospital of Philadelphia advance the search for genetic ... childhood cancer. , , Originating in the peripheral nervous ... childhood and causes 15 percent of all childhood cancer deaths. ...
    Cached Medicine Technology:Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries 2Gene Findings Unlocking Reasons for Neuroblastoma Risk 2Gene Findings Unlocking Reasons for Neuroblastoma Risk 3Gene Findings Unlocking Reasons for Neuroblastoma Risk 4
    (Date:9/16/2014)..., the well-known wedding dress manufacturer and retailer, ... assortment online. Additionally, the firm has launched a promotion ... discounts now, up to 62 percent off. ... it has won a lot of positive reviews for ... also providing big savings on many other items, including ...
    (Date:9/16/2014)... Recently,, one of the most famous dress suppliers in ... gown collection. According to the company’s sales manager, all ... to 69% off) at present. Additionally, all the company’s old ... a frequent caller of your site. I like your products ... quite happy. All items are of good quality. I sincerely ...
    (Date:9/16/2014)... 2014 (HealthDay News) -- Modern forensic techniques are shedding ... have killed King Richard III, the last English monarch ... the king,s skeletal remains, using whole-body CT scans and ... of the 11 injuries he suffered at the Battle ... 1485. The modern forensics revealed that two skull ...
    (Date:9/16/2014)... Lake Worth, FL (PRWEB) September 16, 2014 ... Millennium Treatment Group, they take care to make sure ... best for them. For some, this may include the ... new online therapy program which gives patients the opportunity ... Millennium Treatment Group can provide medical and clinical care ...
    (Date:9/16/2014)... Seattle, WA (PRWEB) September 16, 2014 Duke’s ... with Seattle startups Rebls and Gratafy for ... tech and startup hub is firmly cemented. With the growth of ... number of opportunities for people who work in tech and at ... community, Rebls and Gratafy are happy to host events for their ...
    Breaking Medicine News(10 mins):Health News:New Elegant Evening Wear Assortment Released By 2Health One Shoulder Evening Gown Collection Unveiled Online 2Health News:Modern Forensics Provides Clues to Death of Richard III 2Health News:Millennium Treatment Group Now Offers Online Therapy 2Health News:Seattle Seafood Restaurant Duke’s Chowder House Partners with Rebls & Gratafy for Tech Networking Happy Hour Event. 2Health News:Seattle Seafood Restaurant Duke’s Chowder House Partners with Rebls & Gratafy for Tech Networking Happy Hour Event. 3
    ... parasite that roams with only limited control among the rural ... Trypanosoma cruzi is the triatomine insect, or "kissing bug," which ... bug sucks the blood of mammals, helping T. cruzi ... tend to lie on porches or other areas easily accessible ...
    ... By Dennis Thompson HealthDay Reporter , SUNDAY, July 11 ... expected to lead to an increase in cases of glaucoma, the ... A number of demographic and health trends have increased the number ... These trends include: The aging of America , Growth ...
    ... PhD, CEP, Professor of Public Health and Director of ... will present evidence that supports relationships seen in adolescents ... total body fat and identifies additional potential early markers ... year-old children, including fat in muscle cells, blood pressure, ...
    ... molecular mechanism that increases life span through calorie restriction may ... for Learning and Memory report in the July 11 issue ... been touted as a life-span enhancer because it activates a ... in recent years for their ability to slow the aging ...
    ... testing and immediate antiretroviral treatment (ART) for infected individuals could ... DC, but a new study finds that it would not ... In a paper that will appear in the August ... been released online, researchers find that the so-called "test-and-treat" strategy ...
    ... ... ... Reliable information is essential for governments to formulate policies that would meet people’s needs and ... Population Fund. “With quality data , we can better track and make greater progress ...
    Cached Medicine News:Health News:Dogs may help collar Chagas disease 2Health News:Glaucoma Cases on the Rise in U.S. 2Health News:Glaucoma Cases on the Rise in U.S. 3Health News:LSUHSC study finds early predictors of metabolic syndrome in healthy 7-9 year-olds 2Health News:LSUHSC study finds early predictors of metabolic syndrome in healthy 7-9 year-olds 3Health News:MIT researchers find that Sirtuin1 may boost memory and learning ability 2Health News:Universal HIV testing and immediate treatment could reduce but not eliminate HIV/AIDS epidemic 2Health News:Everyone Counts: Quality Data Essential to Improving People's Lives, Says UNFPA 2
    Lyphochek Whole Blood Control is a unique product designed to monitor immunosuppressants, red cell folate and lead in whole blood assays. This control has three critical levels for each analyte and i...
    Liquichek Whole Blood Volatiles Control is an assayed liquid control for monitoring volatile compounds. This product is available in 2 levels....
    qUAntify Control is designed to monitor the performance of urine dipstick testing. The control is available in 12 mL ready-to-use dropper bottles....
    Lyphochek Urine Bone Markers Control is a bilevel human urine based control designed to monitor tests for urinary markers of osteoporosis management and bone resorption....
    Medicine Products: